Juno Therapeutics, Inc. (NASDAQ:JUNO) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 14,724,068 shares, a decline of 6.4% from the August 15th total of 15,734,670 shares. Based on an average daily volume of 5,210,536 shares, the days-to-cover ratio is presently 2.8 days. Approximately 19.1% of the company’s stock are sold short.
In other Juno Therapeutics news, Director Anthony B. Evnin acquired 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was acquired at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the transaction, the director now owns 66,301 shares of the company’s stock, valued at $1,617,744.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the transaction, the chief financial officer now owns 736,189 shares of the company’s stock, valued at $22,085,670. The disclosure for this sale can be found here. Insiders sold a total of 8,119,219 shares of company stock valued at $220,455,844 over the last quarter. 15.26% of the stock is owned by insiders.
Several large investors have recently made changes to their positions in the stock. Baillie Gifford & Co. boosted its position in shares of Juno Therapeutics by 1.2% during the first quarter. Baillie Gifford & Co. now owns 11,197,863 shares of the biopharmaceutical company’s stock valued at $248,481,000 after buying an additional 135,908 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Juno Therapeutics by 2.1% during the second quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after acquiring an additional 131,864 shares during the period. BlackRock Inc. lifted its holdings in Juno Therapeutics by 2.6% during the second quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after acquiring an additional 110,503 shares during the period. State Street Corp lifted its holdings in Juno Therapeutics by 7.4% during the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after acquiring an additional 222,754 shares during the period. Finally, Capital World Investors lifted its holdings in Juno Therapeutics by 13.8% during the second quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock worth $72,483,000 after acquiring an additional 295,000 shares during the period. 70.76% of the stock is currently owned by institutional investors.
A number of research firms have weighed in on JUNO. Vetr raised Juno Therapeutics to a “buy” rating in a research report on Tuesday, May 23rd. Wedbush reaffirmed a “neutral” rating and set a $24.00 price target on shares of Juno Therapeutics in a research report on Tuesday, June 6th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. BidaskClub raised Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Finally, Zacks Investment Research raised Juno Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company. Juno Therapeutics has a consensus rating of “Hold” and a consensus price target of $34.88.
Shares of Juno Therapeutics (NASDAQ:JUNO) opened at 44.57 on Friday. The company’s market cap is $4.68 billion. The company has a 50-day moving average price of $33.60 and a 200-day moving average price of $26.98. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $47.00.
Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.24). The company had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm’s quarterly revenue was down 22.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.64) EPS. Equities research analysts expect that Juno Therapeutics will post ($3.12) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Juno Therapeutics, Inc. (JUNO) Sees Large Drop in Short Interest” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/09/15/juno-therapeutics-inc-juno-sees-large-drop-in-short-interest.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.